학술논문
Second allogeneic hematopoietic stem cell transplantation in patients with acute leukemia relapsed after allogeneic hematopoietic stem cell transplantation.
Document Type
Academic Journal
Author
Choi Y; Department of Hematology and Oncology, Ulsan University Hospital, University of Ulsan College of Medicine, Ulsan, South Korea.; Choi EJ; Department of Hematology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea.; Lee JH; Department of Hematology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea.; Lee KH; Department of Hematology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea.; Jo JC; Department of Hematology and Oncology, Ulsan University Hospital, University of Ulsan College of Medicine, Ulsan, South Korea.; Park HS; Department of Hematology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea.; Lee YJ; Department of Hematology and Oncology, Ulsan University Hospital, University of Ulsan College of Medicine, Ulsan, South Korea.; Seol M; Department of Hematology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea.; Lee YS; Department of Hematology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea.; Kang YA; Department of Hematology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea.; Jeon M; Department of Hematology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea.; Lee JH; Department of Hematology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea.
Source
Publisher: Munksgaard Country of Publication: Denmark NLM ID: 8710240 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1399-0012 (Electronic) Linking ISSN: 09020063 NLM ISO Abbreviation: Clin Transplant Subsets: MEDLINE
Subject
Language
English
Abstract
The prognosis of patients with acute leukemia relapsed after allogeneic hematopoietic stem cell transplantation (HSCT) is dismal. We aimed to evaluate the outcomes and prognostic factors of the second HSCT (HSCT2) in acute leukemia patients relapsed after the first HSCT (HSCT1). We analyzed 80 patients who received HSCT2 for relapsed acute leukemia in two Korean institutes. All but four patients received HSCT2 from a donor other than matched sibling donor: an unrelated donor (URD) in 30 and a familial haploidentical donor (FHD) in 46. Forty-four patients (55.0%) were in complete remission (CR) or CR with incomplete count recovery (CRi) at HSCT2, and the median time from HSCT1 to relapse was 9 months. The 2-year overall survival (OS) and event-free survival (EFS) were 21.0% and 17.5%, respectively. The outcomes were similar between URD and FHD. Multivariate analysis demonstrated that disease status (active disease vs. CR/CRi) at HSCT2 and remission duration after HSCT1 were independent prognostic factors for OS and EFS after HSCT2. HSCT2 from URD or FHD was feasible in patients with acute leukemia relapsed after allogeneic HSCT. Also, our study confirmed two critical prognostic factors; disease status at HSCT2 and remission duration after HSCT1.
(© 2021 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.)
(© 2021 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.)